Effect of switching medically vulnerable patients with uncontrolled diabetes from isophane insulin human to insulin glargine

American Journal of Health-System Pharmacy

Volumn 63, Issue 19, 2006, Pages 1862-1871

  Erickson, Tiffany N ^a   Devine, Emily Beth ^b   O'Young, Theresa S ^c   Hanson, Laura J ^c   French, Benjamin ^d   Brennan, Cynthia ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c HMC

^d UW ^*

^e HMC   (United States)

Author keywords

Diabetes mellitus; Insulin glargine; Insulin human isophane; Insulins; Race; Substitution; Toxicity

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; AFRICAN AMERICAN; AGED; ASIAN AMERICAN; CLINICAL ARTICLE; COHORT ANALYSIS; DIABETES MELLITUS; DRUG EFFICACY; DRUG SUBSTITUTION; ETHNIC DIFFERENCE; EUROPEAN AMERICAN; FEMALE; GLUCOSE BLOOD LEVEL; HISPANIC; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW;

EID: 33749163374     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050439     Document Type: Review

References (33)

1. Advisory Commission on Consumer Protection and Quality in the Health Care Industry. Quality first: better health care for all Americans. www. hcqualitycommission.gov/final (accessed 2005 Aug 29).
2. Standards of medical care in diabetes. Diabetes Care. 2005; 28:S4-36.
3. Turner RC, Cull CA, Frighi A et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. JAMA. 1999; 281:2005-12.
4. Ratner RE, Hirsch IB, Neifing JL et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care. 2000; 23:576-8.
5. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care. 2000; 23:1130-6.
6. Raskin P, Klaff L, Bergenstal R et al. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care. 2000; 23:1666-71.
7. Rosenstock J, Schwartz SL, Clark CM et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care. 2001; 24:631-6.
8. Fritsche A, Schweitzer MA, Haring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. Ann Intern Med. 2003; 138:952-9.
9. Benedetti MM, Humburg E, Dressler A et al. A one-year, randomized, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res. 2003; 35:189-96.
10. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003; 26:3080-6.
11. Hershon KS, Blevins TC. Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetes. Endocr Pract. 2004; 10:10-7.
12. Garg SK, Paul JM, Karsten JI et al. Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes. Diabetes Technol Ther. 2004; 6:589-95.
13. Fonseca V, Bell DS, Berger S et al. A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. Am J Med Sci. 2004; 328:274-80.
14. Krapek K, King K, Warren SS et al. Medication adherence and associated hemoglobin A1c in type 2 diabetes. Ann Pharmacother. 2004; 38:1357-62.
15. Pladevall M, Williams LK, Potts LA et al. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care. 2004; 27:2800-5.
16. Rhee MK, Slocum W, Ziemer DC et al. Patient adherence improves glycemic control. Diabetes Educ. 2005; 31:240-50.
17. Hill-Briggs F, Gary TL, Bone LR et al. Medication adherence and diabetes control in urban African Americans with type 2 diabetes. Health Psychol. 2005; 24:349-57.
18. Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med. 2005; 118:278-348.
19. Schectman JM, Nadkarni MM, Voss JD. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care. 2002; 25:1015-21.
20. drugstore.com. www.drugstore.com/ (accessed 2005 Sep 7).
21. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997; 50:105-16.
22. Steiner JF, Koepsell TD, Fihn SD et al. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care. 1988; 26:814-23.
23. Long JS, Freese J. Regression models for categorical dependent variables using Stata. 2nd ed. College Station, TX: Stata Press; 2006.
24. Stroup J, Kane MP, Busch RS et al. The utility of insulin glargine in the treatment of diabetes mellitus. Pharmacotherapy. 2004; 24:736-42.
25. Albright ES, Desmond R, Bell DS. Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy. Diabetes Care. 2004; 27:632-3.
26. Plank J, Siebenhofer A, Berghold A et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med. 2005; 165:1337-44.
27. Sokol MC, McGuigan KA, Verbrugge RR et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005; 43:521-30.
28. Warren E, Weatherley-Jones E, Chilcott J et al. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess. 2004; 8:1-57.
29. Chen K, Chang EU, Summers KH et al. Comparison of costs and utilization between users of insulin lispro versus users of regular insulin in a managed care setting. J Manag Care Pharm. 2005; 11:376-82.
30. Harris MI. Racial and ethnic differences in health care access and health outcomes for adults with type 2 diabetes. Diabetes Care. 2001; 24:454-9.
31. Okosun IS, Dever GE. Abdominal obesity and ethnic differences in diabetes awareness, treatment, and glycemic control. Obes Res. 2002; 10:1241-50.
32. Brown AF, Gerzoff RB, Karter AJ et al. Health behaviors and quality of care among Latinos with diabetes in managed care. Am J Public Health. 2003;93:1694-8.
33. Gallegos-Macias AR, Macias SR, Kaufman E et al. Relationship between glycemic control, ethnicity, and socioeconomic status in Hispanic and white non-Hispanic youths with type 1 diabetes mellitus. Pediatr Diabetes. 2003; 4:19-23.